Abstract
1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) is an important hormone that regulates metabolism of calcium and phosphorus in small intestine, kidney, and bone, and its physiological action is expressed as ligand-dependent transcription activity mediated by vitamin D receptor (VDR). The VDR is found in various organs and cells including small intestine, kidney, and bone. In addition to the regulation of calcium metabolism, 1,25(OH)2D3 is involved in various biological reactions such as differentiation induction, antiproliferative effect, immunomodulatory effect, and regulation of cytokine and parathyroid hormone secretion. Thus, 1,25(OH)2D3 is expected to become a therapeutic drug for various related diseases. At present, a number of vitamin D derivatives are clinically applied to psoriasis, secondary hyperparathyroidism and osteoporosis but hypercalcemia and hypercalciuria are major concerns. Therefore, the current focus is directed toward new vitamin D derivatives with weak calcemic effects and a wide therapeutic window. In this summary, recent developments of new vitamin D derivatives for application in clinical treatment are described.
Keywords: Vitamin D, vitamin D receptor (VDR), nuclear receptor
Current Topics in Medicinal Chemistry
Title: Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery
Volume: 6 Issue: 12
Author(s): Tadakatsu Takahashi and Kazumi Morikawa
Affiliation:
Keywords: Vitamin D, vitamin D receptor (VDR), nuclear receptor
Abstract: 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) is an important hormone that regulates metabolism of calcium and phosphorus in small intestine, kidney, and bone, and its physiological action is expressed as ligand-dependent transcription activity mediated by vitamin D receptor (VDR). The VDR is found in various organs and cells including small intestine, kidney, and bone. In addition to the regulation of calcium metabolism, 1,25(OH)2D3 is involved in various biological reactions such as differentiation induction, antiproliferative effect, immunomodulatory effect, and regulation of cytokine and parathyroid hormone secretion. Thus, 1,25(OH)2D3 is expected to become a therapeutic drug for various related diseases. At present, a number of vitamin D derivatives are clinically applied to psoriasis, secondary hyperparathyroidism and osteoporosis but hypercalcemia and hypercalciuria are major concerns. Therefore, the current focus is directed toward new vitamin D derivatives with weak calcemic effects and a wide therapeutic window. In this summary, recent developments of new vitamin D derivatives for application in clinical treatment are described.
Export Options
About this article
Cite this article as:
Takahashi Tadakatsu and Morikawa Kazumi, Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864917
DOI https://dx.doi.org/10.2174/156802606777864917 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alternative Gene Therapy Strategies for the Repair of Craniofacial Bone Defects
Current Gene Therapy Advances in the Use of Stem Cells and Tissue Engineering Applications in Bone Repair
Current Stem Cell Research & Therapy Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Role of ZEB Family Members in Proliferation, Metastasis, and Chemoresistance of Prostate Cancer Cells: Revealing Signaling Networks
Current Cancer Drug Targets Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets A Novel Fluorescence-Labeled Curcumin Conjugate: Synthesis, Evaluation and Imaging on Human Cell Lines
Current Pharmaceutical Design Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children
Reviews on Recent Clinical Trials The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Transcriptionomic Study on Apoptosis of SKOV-3 Cells Induced by Phycoerythrin from <i>Gracilaria lemaneiformis</i>
Anti-Cancer Agents in Medicinal Chemistry Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry